Skip to main content

UroGen Pharma Ltd 10-Q for FY2026 Q3

UroGen Pharma Ltd. (URGN)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

UroGen Pharma Ltd filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

UroGen reported revenue of 89,001 thousand dollars for the quarter ended September 30, 2026, up from 27,482 thousand a year earlier. Its net loss narrowed to 1,462 thousand dollars from 33,347 thousand, and cash and marketable securities totaled $90.5 million as of September 30, 2026. The company believes it has sufficient cash to fund operations beyond one year. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$89M
up 223.9% from $27.48M a year earlier
Net loss
$1.46M
compared with a net loss of $33.35M a year earlier